Drug Response - adverse effect or efficacy

ACE Inhibitor (ACE-I) induced cough

ACE-I induced cough is a common side effect of use of ACE inhibitors, one of the most common class of antihypertensives.  The frequency of ACEI-induced cough varies based on ancestry.  A GWAS of ACEI cough using this algorithm in the eMERGE Network identified KCNIP4 as associated with this phenotype, which was validated in two replication cohorts. 

Cases are those with ACEI cough.  Controls are those exposed to ACEI without adverse events noted and not switched to angiotensin receptor blockers (ARBs).  

Algorithm validated - December 12, 2012.

Owner Phenotyping Groups: 
eMERGE Vanderbilt Group
View Phenotyping Groups: 
eMERGE Phenotype WG
Final

Clopidogrel Poor Metabolizers

Note: Attached documents contain full case definition and two different control definitions.  One is for controls with 2 years of follow up, the other for controls with 1 year of follow up.  All available controls with 2 years of follow up were used in Vanderbilt's study.  The control population was supplemented by controls with only 1 year of follow up.  At the time of study, many of the available controls had experienced their qualifying events somewhat recently and 2 years had not yet passed for full follow up.

 

Owner Phenotyping Groups: 
VESPA - Vanderbilt Electronic Systems for Pharmacogenomic Assessment
View Phenotyping Groups: 
Denny’s Group at Vandy
VESPA - Vanderbilt Electronic Systems for Pharmacogenomic Assessment
Final

Drug Induced Liver Injury

An algorithm to identify inpatients who have had an acute episode of drug induced liver injury (DILI).

Summary of drug-induced liver injury algorithm

Inclusion criteria

A. Suspect DILI? (NOTE: baseline population is institution specific.  See institution implementation details)

1.     Liver injury AND Exposure to drug (NOTE: medications are institution specific. See institution implementation details)

2.     Temporal relationship of exposure to drug and liver injury diagnosis.

Owner Phenotyping Groups: 
eMERGE Mount Sinai Group
View Phenotyping Groups: 
eMERGE Phenotype WG
Final

PGx medication risk prediction model

This algorithm predicts those who are going to be exposed to warfarin, simvastatin, or clopidogrel as three medications that have known pharmacogenomic influences.  This algorithm was used to select individuals for the Vanderbilt PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment) program, which prospectively tests individuals at risk of needing medications whose efficacy is effected by genetic variants.  

 

For more information on PREDICT, see http://mydruggenome.org.

Owner Phenotyping Groups: 
eMERGE Vanderbilt Group
View Phenotyping Groups: 
Denny’s Group at Vandy
eMERGE Phenotype WG
Final

Post-event Pain algorithm

Pain is a personal, multidimensional experience in which genetic biomarkers has a main role in determining pain sensitivity, perception and tolerance. Pain is a major concern for surgical patients and post-operative pain management still present a major challenge both in inpatient or outpatient settings. Apart from genetic factors, there are many other variables that may affect pain perception for example, pretreated patients may require less post-surgical medications, and they may recover more quickly.

Owner Phenotyping Groups: 
eMERGE CCHMC Group
View Phenotyping Groups: 
eMERGE Phenotype WG
Final

Statins and MACE

Phenotype Description:  Patients on statins for primary prevention who develop an AMI or 1st AMI. 

Below are algorithms used to identify AMI and 1st AMI cohort at BioVU. If you have questions regarding any of the information presented on this page, you may contact either:

Wei-Qi Wei at wei-qi.wei@vanderbilt.edu

Joshua Denny at josh.denny@vanderbilt.edu

 

             

Owner Phenotyping Groups: 
eMERGE Vanderbilt Group
PGPop WG
View Phenotyping Groups: 
eMERGE Phenotype WG
PGPop WG
Final

Pages